Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
NEW Guidance on the Presentation of Disease Burden in Advertising
-
Hello @manufacturer and @agency
PAAB is pleased to announce that we have broadened our approach to disease burden presentations within advertising. The new guidance can be found under the Resources tab on the PAAB website or by following this link to the Guidance on the Presentation of Disease Burden in Advertising.
PAAB will start accepting submissions under the new guidance as of February 19th, 2024 to allow a 6 week window for all organizations to familiarize themselves with this document prior to launch. You will also find a Case Examples document which has been designed to provide additional rationale and context for application.
Thank you to the 15+ agencies and manufacturers who provided feedback on the development of this revised approach.
PAAB would also like to thank bMod, CORE Health Communications, FCB Health Canada and GSW for their invaluable assistance in developing examples for this guidance.
